

1-17-2007

Examination of the New α -(2''Z-Fluoro)vinyl Trigger with Lysine Decarboxylase: The Absolute Stereochemistry Dictates the Reaction Course

Kannan R. Karukurichi

University of Nebraska - Lincoln

Roberto de la Salud-Bea

University of Nebraska - Lincoln

Wan Jin Jahng

University of Nebraska - Lincoln

David B. Berkowitz

University of Nebraska - Lincoln, dberkowitz1@unl.edu

Follow this and additional works at: <http://digitalcommons.unl.edu/chemistryberkowitz>

 Part of the [Chemistry Commons](#)

Karukurichi, Kannan R.; Salud-Bea, Roberto de la; Jahng, Wan Jin; and Berkowitz, David B., "Examination of the New α -(2''Z-Fluoro)vinyl Trigger with Lysine Decarboxylase: The Absolute Stereochemistry Dictates the Reaction Course" (2007). *David Berkowitz Publications*. 12.

<http://digitalcommons.unl.edu/chemistryberkowitz/12>

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in David Berkowitz Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Published in final edited form as:

J Am Chem Soc. 2007 January 17; 129(2): 258–259. doi:10.1021/ja067240k.

Examination of the New α -(2'-Z-Fluoro)vinyl Trigger with Lysine Decarboxylase: The Absolute Stereochemistry Dictates the Reaction Course

Kannan R. Karukurichi, Roberto de la Salud-Bea, Wan Jin Jahng, and David B. Berkowitz*

Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304

Abstract

The first examination of a terminal α -fluorovinyl trigger in an amino acid decarboxylase active site is reported. To investigate the enantiospecificity of inactivation with this new AADC trigger, an enantioselective synthesis of L- α -(2'-Z-fluoro)vinyllysine and its D-antipode has been developed. Control of stereochemistry is achieved through introduction of the amino acid side chain via alkylation of a chiral vinylglycine-derived dienolate. Facial selectivity is conferred by a *trans*-2'-(β -naphthyl)-2'-propylcyclohexyl ester auxiliary, available in both antipodal forms (Comins protocol). The alkylation employs a new electrophile, N-*p*-methoxybenzyl-N-(2'-trimethylsilylthanesulfonyl)-4-iodobutylamine, for convergent installation of the lysine side chain. Vinyl to 2'-fluorovinyl interconversion then provides L- and D- α -(2'-Z-fluoro)vinyllysine in 97–99% ee, as demonstrated by chiral HPLC. Both time-dependent enzyme kinetics and ^{19}F NMR reveal striking differences in the behavior of these two antipodes in the lysine decarboxylase active site. The L-antipode displays time dependent inactivation ($t_{1/2} = 3 \pm 1$ min.; $K_I = 86 \pm 22$ μM) whereas the D-antipode behaves as a substrate, being completely turned over to α -(2'-Z-fluoro)vinylcadaverine. Titration of LDC with varying amounts of L- α -(2'-Z-fluoro)vinyllysine provides an estimate of 20 ± 3 for the partition ratio for this antipode. ^{19}F NMR provides a more detailed account of the inactivation with the L-antipode, revealing that 1 in 3.2 turnovers of this mechanism-based inhibitor result in errant protonation (required by design), with 1 in 5 errant protonation events leading to LDC inactivation. This gives an overall partition ratio of 16 ± 2 . Fluoride-selective electrode measurements are in agreement with ^{19}F NMR estimates of [fluoride] released.

Mechanism-based enzyme inactivators (MBEI's)^{1,2} are useful bioorganic tools to study enzyme mechanism and to modulate metabolic flux. Moreover, of the over 300 enzyme-targeted drugs in the FDA Orange Book, most may be considered broadly “mechanism-based.”³ As such, some combinatorial libraries are now built around MBEI trigger motifs.⁴ Recently, “suicide triggers” have also found application in screens for catalytic antibodies⁵ and in activity-based proteomics.⁶

We describe here the first successful halovinyl trigger for amino acid decarboxylase (AADC) inactivation, of which we are aware. Among MBEI's for AADC's, DFMO (α -difluoromethylornithine), used clinically for parasitic diseases and as a potential chemopreventive agent,⁷ probably is the benchmark. The mechanism of action of the α -difluoromethyl trigger in the ornithine decarboxylase (ODC) active site has now been elucidated by a combination of MS⁸ and X-ray methods,⁹ and the non-enantioselective nature of its inactivation has been established.¹⁰

We set out to develop an α -(2'-fluoro)vinyl (2'FV) trigger for AADC inactivation with projected mechanism(s) as outlined in Scheme 1. The design envisions the normal transaldimination (to **I**), and α -decarboxylation (gives **II**) steps, followed by an errant protonation at either C_{4'} of the cofactor (to **IV**) or at C_γ of the "suicide substrate." The former pathway finds precedence in the now crystallographically established¹¹ Michael addition mechanism¹² of the antiepileptic drug, Vigabatrin, though for this target, GABA transaminase, C₄, is the normal locus of protonation. The latter C_γ pathway can branch into a nucleophilic Metzler enamine pathway,¹¹ and/or into a second electrophilic pathway, initiated by γ -fluoride expulsion out of intermediate **VIII**,¹³ rather than Mannich condensation.

Note again that all three putative AADC inactivation pathways require that the enzyme be directed into a mistaken protonation of quinonoid intermediate **II**. The literature provides insight as to how this detour pathway might be promoted. It is known that installation of an α -methyl group, to generate a quaternary AA, results in increased errant (C_{4'}) protonation in the cognate AADC (from typically 0.01–0.1% up to 4% frequency for ODC).¹⁴ So, the placement of the (2'FV) trigger at a quaternary α -center is critical to our design, and is to serve the dual purpose of (i) dictating specificity for AADC's over enzymes that labilize the α -proton (e.g. transaminases, racemases, β - and γ -replacement enzymes), and (ii) promoting the requisite errant protonation.

We chose L-lysine decarboxylase (LDC) as a model enzyme in which to test this new AADC trigger, as we had access to multi-milligram quantities of the *Hafnia alvei* LDC.¹⁵ Furthermore, this class of bacterial LDC was reported to be resistant to covalent modification with the α -difluoromethyl trigger.¹⁶

A stereoselective synthesis of each antipode of the targeted inactivator was achieved as outlined in Scheme 2. The quaternary center is introduced by alkylation of a chiral vinylglycine-derived dianionic dienolate.¹⁷ As illustrated, our working model for such systems involves (i) the use of α -nitrogen-based amidate chelation to control enolate geometry and (ii) the application of auxiliaries of the "arylmethyl" variety to control facial selectivity.

The use of dienolates outfitted with the Comins auxiliary (available in both antipodal forms)¹⁸ here provides a potentially generalizable method to access both enantiomers of sought after quaternary AA's. Following side chain installation, conversion of the α -vinyl group to a 2'Z-fluorovinyl group proceeds smoothly, following to our recently disclosed protocol.¹⁹

L- α -(2'Z-Fluoro)vinyllysine displays time dependent inactivation of LDC, whereas its mirror image displays little to no inactivation. Kitz-Wilson of the the L-2'FVL data, yields $k_{\text{inact}} = 0.26 \pm 0.07 \text{ min}^{-1}$ and $K_I = 86 \pm 22 \text{ }\mu\text{M}$. This is comparable to the k_{inact} values seen for both antipodes of DFMO and (S)-Vigabatrin. The K_I value is higher than that seen for L-DFMO ($\sim 1.3 \text{ }\mu\text{M}$),¹⁰ but significantly lower than that seen for (S)-Vigabatrin ($\sim 3 \text{ mM}$).²⁰ Inactivation was functionally irreversible (dialysis). Curvature in $\ln(E_t/E_0)$ vs. t plots was observed, suggestive of significant partitioning into natural or unnatural turnover pathways. In fact, a titration of the enzyme with varying I:E ratios provides an estimate of the partition ratio (total turnovers per inactivation event) of $\sim 20 \pm 3$ (Fig. 1).

Fluorine serves both a mechanistic and a labeling role in this trigger. ¹⁹F NMR monitoring,²¹ of the individual FVL-antipodes (Fig. 2) shows the D-enantiomer to be exclusively a *substrate*, whereas the L-antipode is a *suicide substrate*. Inactivation of $15 \text{ }\mu\text{M}$ LDC produces $168 \pm 14 \text{ }\mu\text{M}$ α -(2'fluoro)vinylcadaverine (FVC) turnover product (matches authentic sample) and $70 \pm 13 \text{ }\mu\text{M}$ fluoride.²² The fluoride value was confirmed with an ion-specific electrode ($78 \pm 5 \text{ }\mu\text{M}$).

Since all errant protonations are projected to release fluoride, one can estimate that 1 in 3.4 decarboxylations leads to errant protonation (29%!), with 1 in 5 errant protonation events leading to LDC inactivation. This gives an overall partition ratio of 16 ± 2 . The high errant protonation rate (~8 times the maximum value produced by α -methylation) seen in this model AADC active site is promising, as altered protonation is required for trigger actuation. γ -Protonation provides the simplest mechanism for release of four excess equivalents of fluoride, but this does not exclude any of the three pathways put forth for the inactivation step itself. This must await the results of further studies. Given the success in driving errant protonation with L-FVL and its favorable k_{inact} , it will be of interest to examine this trigger in other AADC active sites. The remarkable enantio-discrimination observed stands in stark contrast to the case of DFMO, and underscores the value of interrogating individual antipodes in MBEI studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the NSF (CHE-0616840) and the NIH (CA 62034 and RR016544-01) for support of unnatural AA synthesis and MBEI efforts in our laboratory.

References

1. (a) Schramm VL. *Encyclopedia of Biological Chemistry* 2004;2:31–37. (b) Silverman RB. *Meth Enzymol* 1995;249:240–283. [PubMed: 7791614]
2. Examples: (a) Qiao C, Ling KQ, Shepard EM, Dooley DM, Sayre LM. *J Am Chem Soc* 2006;128:6206–19. [PubMed: 16669691] (b) Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. *J Am Chem Soc* 2006;128:1092–3. [PubMed: 16433522] (c) Culhane JC, Szewczuk LM, Liu X, Da G, Marmorstein R, Cole PA. *J Am Chem Soc* 2006;128:4536–7. [PubMed: 16594666] (d) Lee Y, Ling KQ, Lu X, Silverman RB, Shepard EM, Dooley DM, Sayre LM. *J Am Chem Soc* 2002;124:12135–43. [PubMed: 12371853] (e) McCann AE, Sampson NS. *J Am Chem Soc* 2000;122:35–39.
3. Robertson JG. *Biochemistry* 2005;44:5561–5571. [PubMed: 15823014]
4. Wood WJL, Huang L, Ellman JA. *J Comb Chem* 2003;5:869–80. [PubMed: 14606817]
5. (a) Betley JR, Cesaro-Tadic S, Mekhalafia A, Rickard JH, Denham H, Partridge LJ, Pluckthun A, Blackburn GM. *Angew Chem, Int Ed* 2002;41:775–777. (b) Gao C, Lin CH, Lo CHL, Mao S, Wirsching P, Lerner RA, Janda KD. *Proc Natl Acad Sci USA* 1997;94:11777–11782. [PubMed: 9342313]
6. (a) Evans MJ, Cravatt BF. *Chem Rev* 2006;106:3279–3301. [PubMed: 16895328] (b) Alexander JP, Cravatt BF. *Chem Biol* 2005;12:1179–1187. [PubMed: 16298297]
7. Gerner EW, Meyskens FL Jr. *Nature Rev Cancer* 2004;4:781–92. [PubMed: 15510159]
8. Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. *J Biol Chem* 1992;267:150–158. [PubMed: 1730582]
9. Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ. *Biochemistry* 1999;38:15174–15184. [PubMed: 10563800]
10. Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW. *Biochemical J* 2003;375:465–70.
11. Storici P, De Biase D, Bossa F, Bruno S, Mozzarelli A, Peneff C, Silverman RB, Schirmer T. *J Biol Chem* 2004;279:363–373. [PubMed: 14534310]
12. Nanavati SM, Silverman RB. *J Am Chem Soc* 1991;113:9341–49.
13. For evidence of such a pathway with γ -(2'-fluoro)vinyl-GABA and GABA transaminase, see: Silverman RB, Bichler KA, Leon AJ. *J Am Chem Soc* 1996;118:1253–1261.
14. (a) Akhtar M, Stevenson DE, Gani D. *Biochemistry* 1990;29:7648–7660. [PubMed: 2271524] (b) Choi SY, Churchich JE. *Eur J Biochem* 1986;160:515–520. [PubMed: 3536509] (c) O'Leary MH,

- Herreid RM. *Biochemistry* 1978;17:1010–14. [PubMed: 629941] (d) O’Leary MH, Baughn RL. *J Biol Chem* 1977;252:7168–73. [PubMed: 561784]
15. Beier H, Fecker LF, Berlin J. *Z Naturforsch C* 1987;42:1307–12.
16. Yamamoto S, Imamura T, Kusaba K, Shinoda S. *Chem Pharm Bull* 1991;39:3067–3070. [PubMed: 1799949]
17. Berkowitz DB, McFadden JM, Sloss MK. *J Org Chem* 2000;65:2907–2918. [PubMed: 10814177]
18. (a) Storici P, Qiu J, Schirmer T, Silverman RB. *Biochemistry* 2004;43:14057–14063. [PubMed: 15518554] (b) Bhattacharjee MK, Snell EE. *J Biol Chem* 1990;265:6664–6668. [PubMed: 2182624] (c) Badet B, Roise D, Walsh CT. *Biochemistry* 1984;23:5188–94. [PubMed: 6439236] (d) Ueno H, Likos JJ, Metzler DE. *Biochemistry* 1982;21:4387–4393. [PubMed: 6812625] (e) Likos JJ, Ueno H, Feldhaus RW, Metzler DE. *Biochemistry* 1982;21:4377–4386. [PubMed: 6812624]
19. Berkowitz DB, De la Salud-Bea R, Jahng WJ. *Org Lett* 2004;6:1821–1824. [PubMed: 15151423]
20. Pan Y, Qiu J, Silverman RB. *J Med Chem* 2003;46:5292–5293. [PubMed: 14640537]
21. Examples of monitoring E-I complexes with ^{19}F NMR: (a) Kim DH, Lees WJ, Walsh CT. *J Am Chem Soc* 1994;116:6478–6479. (b) Parisi MF, Abeles RH. *Biochemistry* 1992;31:9429–9435. [PubMed: 1327115]
22. (a) Araoz R, Anhalt E, Rene L, Badet-Denisot MA, Courvalin P, Badet B. *Biochemistry* 2000;39:15971–15979. [PubMed: 11123924] (b) Xu Y, Abeles RH. *Biochemistry* 1993;32:806–811. [PubMed: 8422385] (c) Phillips RS, Dua RK. *Arch Biochem Biophys* 1992;296:489–496. [PubMed: 1632641]




Figure 1.
Titration of LDC with L-2'FVL (two trials, color-coded)






Figure 2.

^{19}F NMR spectral acquisitions monitoring the reaction course taken by the L- (top) and D- enantiomer (bottom) of α -(2'Z-fluoro)vinyllysine ([I]:[E] = 75:1), upon incubation with *Hafnia alvei* LDC (15 μM) at pH 6.0, for the indicated times. Parallel kinetic assays show 92% inactivation for the L-antipode in 10 min, and complete knockout in <1 h, accounting for the invariant NMR spectrum for L-FVL (essentially unchanged @ t = 16 h, see SI).



Scheme 1.
Projected Mechanisms for the 2'FV-AADC Trigger



Scheme 2.
Stereoselective Introduction of the 2'FV-AADC Trigger